Which aspect is specifically scrutinized in the European Product Quality Review (PQR) that might not be emphasized in the U.S. APR? Response:

Question

Options

• AManufacturing process deviations
• BMarketing strategies effectiveness
• CFinancial performance over the fiscal year
• DRaw material supply chain sustainability

• A
  83% (15)
• B
  11% (2)
• D
  6% (1)

Explanation

Manufacturing process deviations (A) are a core focus of the EU PQR framework, which requires systematic review and trending of all deviations, non-conformances, and failures across the product lifecycle. While the U.S. APR also covers deviations, the EU PQR places particular regulatory emphasis on deviation management as a quality risk tool, requiring documented trend analysis and corrective action assessment in a structured way.

Why the distractors are wrong:

• B (Marketing strategies): Marketing effectiveness is a commercial/business function - neither the PQR nor the APR is concerned with it.
• C (Financial performance): Fiscal metrics belong to business reporting, not pharmaceutical quality system reviews.
• D (Raw material supply chain sustainability): While raw material specifications and supplier qualification are reviewed, sustainability in the environmental/ESG sense is outside the scope of both quality review systems.

Memory tip: Think of the EU PQR as "Process Quality Review" - the word process signals its deep dive into how deviations from the manufacturing process are captured, trended, and corrected. If a batch went wrong, the EU auditor wants to see it documented and analyzed, not just noted.

No community discussion yet for this question.